Available antiepileptic drugs interact with a variety of different molecular targets. The mechanism of action of most anticonvulsants is most often complex with a number of affected regions. The combination of mechanisms of action of drugs in particular proportions can possibly determine the showcase of its antiepileptic activity. The common factor between the different supposed mechanisms for a number of drugs includes the possibility for modulating the excitatory and inhibitory neurotransmission through effects upon the voltage-gated ion channels, synaptic plasticity, heterogeneous receptors, and metabolism of neurotransmitters. There are controversial data on the extent to which a specific action can be the reason for the wholesome anticonvulsive characteristics of various medications, as well as the relation with the presence of undesired drug effects. The complexity of the action of some antiepileptic drugs creates conditions for optimal choice during therapy. In many cases, the insufficient familiarity with individual genetic differences and the disease related receptor damages can hinder defining a particular drug action. Characterizing the mechanisms of action of the present antiepileptic medications would increase the understanding for the pathophysiological mechanisms of epileptic seizures, as well as the development of new therapeutic strategies. The development of novel antiepileptic drugs and the ongoing research regarding the mechanism of action of established antiepileptic drugs, are continuously increasing the level of complexity in the spectrum of molecular targets relevant for epilepsy therapy. The current state of knowledge as well as the limitations in our understanding should guide future research aiming for a more detailed elucidation of the impact of genetics and pathophysiological mechanisms on interindividual differences in expression and function of antiepileptic drug targets.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Bagal SK, Brown AD, Cox PJ et al. Ion channels as therapeutic targets: a drug discovery perspective. J Med Chem 2013;56;3:593-624.
2. Bagal SK, Marron BE, Owen RM, Storer RI, Swain NA. Voltage gated sodium channels as drug discovery targets. Channels 2015;9;6:360-366.
3. Benarroch, EE. GABAA receptor heterogeneity, function, and implications for epilepsy. Neurology 2007;68:612-614.
4. Beydoun A, D’Souza J, Hebert D, et al. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9:33-42.
5. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nature Reviews Drug Discovery 2010;9:68-82.
6. Britton JW, Zakaria TM, Benarroch E. Mechanisms of action of antiepileptic drugs. In: Cascino GD, Sirven JI. Adult Epilepsy. John Wiley & Sons 2011:115-126.
7. Catterall WA, Few AP. Calcium channel regulation and presynaptic plasticity. Neuron 2008;59:882-901.
8. Corbin-Leftwich A, Mossade SM, Ha J et al. Retigabine holds KV7 channels open and stabilizes the resting potential. J Gen Physiol 2016;147;3:229-241.
9. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73:157-169.
10. Fattore C, Perucca E. Novel medications for epilepsy. Drugs 2011;71:2151-2178.
11. French JA, Faught E. Rational polytherapy. Epilepsia 2009;50;8:63-68.
12. Gao L, Li S. Emerging drugs for partial-onset epilepsy: a review of brivaracetam. Ther Clin Risk Manag 2016;12:719-734.
13. Ghasemi M, Schachter SC. The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy Behav 2011;22;4:617-640.
14. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012;53:412-424.
15. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, et al. Pharmacological disruption of calcium channel trafficking by the alpha2 delta ligand gabapentin. Proceedings of the National Academy of Sciences of the United States of America 2008;105:3628-3633.
16. Henshall DC, Diaz-Hernandez M, Miras-Portugal MT, Engel T. P2X receptors as targets for the treatment of status epilepticus. Front Cell Neurosci 2013;7:237.
17. Imbrici P, Camerino DC, Tricarico D. Major channels involved in neuropsychiatric disorders and therapeutic perspectives. Front Genet 2013;4:76.
18. Jin LJ, Schlesinger F, Song YP, Dengler R, Krampfl K. The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patchclamp study. Pharmacology 2010;85:54-62.
20. Lee CY, Chen CC, Liou HH. Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol 2009;158:1753-1762.
21. Löscher W. Valproate: a review of its basic pharmacology after 35 years of clinical use in pharmacotherapy of epilepsy. CNS Drugs 2002;16;10:669-694.
22. Łuszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacology Reports 2009;61;2:197-216.
23. Mantegazza M, Curia G, Biagini G, et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010;9:413-424.
24. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics 2007;4:18-61.
25. Miceli F, Soldovieri MV, Ambrosino Pet al. Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. J Neurosci 2015;35;9:3782-3793.
26. Mumoli L, Palleria C, Gasparini S et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther 2015;9:5719-5725.
27. Poolos NP. Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Ion Channelopathy in Epilepsy. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper‘s Basic Mechanisms of the Epilepsies. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US) 2012.
28. Porter RJ, Baulac M, Nohria V. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe. Epilepsy Research 2010;89:163-175.
29. Potschka H. Pharmacological treatment strategies: Mechanisms of antiepileptic drugs. Epileptology 2013;1:31-37.
30. Rogawski MA, Bazil CW. New Molecular Targets for Antiepileptic Drugs: α2δ, SV2A, and Kv7/KCNQ/M Potassium Channels. Current Neurology and Neuroscience Reports 2008;8;4:345-352.
31. Schipper S, Aalbers MW, Rijkers K, Swijsen A, Rigo JM, et al. Tonic GABAA Receptors as Potential Target for the Treatment of Temporal Lobe Epilepsy. Mol Neurobiol 2016; 53;8:5252-5265.
32. Sigel E, Luscher BP. A closer look at the high affinity benzodiazepine binding site on GABAA receptors. Current Topics in Medicinal Chemistry 2011;11:241-246.
33. Stas JI, Bocksteins E, Jensen CS, Schmitt N, Snyders DJ. The anticonvulsant retigabine suppresses neuronal KV2-mediated currents. Sci Rep 2016;6:350-380.
34. Tambucci R, Basti C, Maresca M, Coppola G, Verrotti A. Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy. Neuropsychiatr Dis Treat 2016;12:1251-1260.
35. Tang FR, Bradford, HF, Ling EA. Metabotropic glutamate receptors in the control of neuronal activity and as targets for development of anti-epileptogenic drugs. Curr Med Chem 2009;16:2189-2204.
36. Wuttke TV, Lerche H. Novel Anticonvulsant Drugs Targeting Voltage-Dependent Ion Channels. Expert Opinion on Investigational Drugs 2006;15:1167-1177.